No advantage of a rotational continuation phase in acute lymphoblastic leukemia in childhood treated with a BFM back-bone therapy

Pediatric Blood and Cancer

Volumn 57, Issue 1, 2011, Pages 47-55

  Felice, Maria S ^a   Rossi, Jorge G ^a   Gallego, Marta S ^a   Alfaro, Elizabeth M ^a   Zubizarreta, Pedro A ^a   Fraquelli, Lidia E ^a   Alonso, Cristina N ^a   Guitter, Myriam R ^a   Scopinaro, Marcelo J ^a  

^a HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

Author keywords

Acute lymphoblastic leukemia; BFM back bone; Childhood; Continuation phase; Maintenance phase; Randomized studies; Treatment

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; IFOSFAMIDE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TENIPOSIDE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER RADIOTHERAPY; CANCER RISK; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; CHILD, PRESCHOOL; DAUNORUBICIN; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDNISONE; RISK FACTORS; SURVIVAL RATE; VINCRISTINE;

EID: 79955720286     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23097     Document Type: Article

References (22)

1. Pui CH, Evans WE. Acute lymphoblastic leukemia (review). N Engl J Med 1998; 339: 605-615.
2. Coustan-Smith E, Sancho J, Hancock ML, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000; 96: 2691-2696.
3. Reiter A, Schrappe M, Ludwig WD, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the Multicenter Trial ALL-BFḾ86. Blood 1994; 84: 3122-3133.
4. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 2000; 95: 3310-3322.
5. Rivera GK, Raimondi S, Hancock M, et al. Improved outcome in childhood acute lymphoblastic leukemia with reinforced early treatment and rotational combination chemotherapy. Lancet 1991; 337: 61-66.
6. Sackmann-Muriel F, Felice MS, Zubizarreta P, et al. Improved outcome in higher-risk acute lymphoblastic leukaemia with a hybrid (Berlin-Frankfurt-Münster/St Jude's) therapy. Int J Pediatr Hematol Oncol 1996; 3: 439.
7. Sackmann-Muriel F, Felice M, Zubizarreta P, et al. Treatment results in childhood acute lymphoblastic leukemia with a modified ALL-BFM'90 protocol: Lack of improvement in high-risk group. Leuk Res 1999; 23: 331-340.
8. Pieters R, Schrappe M, De Lorenzo P, et al. Outcome of infants less than one year of age with acute lymphoblastic leukemia treated with the Interfant-99 protocol. Lancet 2007; 370: 240-250.
9. Bene MC, Castoldi G, Knapp W, et al. European Group for the Immunological Characterization of Leukemias (EGIL): Proposal for the immunological classification of acute leukemias. Leukemia 1995; 9: 1783-1786.
10. Shaffer LG, Slovak ML, Campbell LJ, editors. ISCN: International System for Human Cytogenetic Nomenclature, Basel, Switzerland: S. Karger AG; 2009.
11. Riehm H, Gadner H, Henze G, et al. Results and significance of six randomized trials in four consecutive ALL-BFM studies. Hematol Blood Transfus 1990; 33: 439-450.
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1995; 53: 457-481.
13. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation on each patient. II. Analysis and examples. Br J Cancer 1997; 35: 1-39.
14. Tarone RE, Wara J. On distribution-free test for equality of survival distribution. Biometrika 1997; 64: 156.
15. Rossi J, Felice M, Bernasconi A, et al. Acute leukemia of dendritic cell lineage in children: Incidence, biological characteristics and outcome. Leuk Lymphoma 2006; 47: 715-725.
16. Conter V, Valsecchi MG, Silvestri D, et al. Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: A multicentre randomised trial. Lancet 2007; 369: 123-131.
17. Chauvenet AR, Martin PL, Devidas M, et al. Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: A report from Children's Oncology Group Study P9201. Blood 2007; 110: 1105-1111.
18. De Moerloose B, Suciu S, Bertrand Y, et al. Improved outcome with pulses of vincristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL): Report of the EORTC randomized phase 3 trial 58951. Blood 2010; 116: 36-44.
19. Ribeiro RC, Rivera GK, Hudson M, et al. An intensive re-treatment for children with an isolated CNS relapse of acute lymphoblastic leukemia. J Clin Oncol 1995; 13: 333-338.
20. Bleyer WA, Sather HN, Nickerson HJ, et al. Monthly pulses of vincristine and prednisone prevent bone marrow and testicular relapse in low-risk childhood acute lymphoblastic leukemia: A report of the CCG-161 study by the Childrens Cancer Study Group. J Clin Oncol 1991; 9: 1012-1021.
21. Pinkel D, Hernandez K, Borrella L, et al. Drug dosage and remission duration in childhood lymphocytic leukemia. Cancer 1971; 27: 247-256.
22. Chessells JM, Bailey C, Richards SM. Intensification of treatment and survival in all children with lymphoblastic leukaemia: Results of UK Medical Research Council trial UKALL X. Lancet 1995; 345: 143-148.